-
1 Comment
Hunan Fangsheng Pharmaceutical Co., Ltd is currently in a long term uptrend where the price is trading 2.6% above its 200 day moving average.
From a valuation standpoint, the stock is 80.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.9.
Hunan Fangsheng Pharmaceutical Co., Ltd's total revenue rose by 23.4% to $342M since the same quarter in the previous year.
Its net income has increased by 33.3% to $22M since the same quarter in the previous year.
Finally, its free cash flow grew by 170.4% to $23M since the same quarter in the previous year.
Based on the above factors, Hunan Fangsheng Pharmaceutical Co., Ltd gets an overall score of 5/5.
| ISIN | CNE100001VG6 |
|---|---|
| Exchange | SHG |
| CurrencyCode | CNY |
| Industry | Drug Manufacturers-Specialty & Generic |
| Sector | Healthcare |
| PE Ratio | 20.55 |
|---|---|
| Target Price | None |
| Market Cap | 6B |
| Beta | 0.52 |
| Dividend Yield | 1.7% |
Hunan Fangsheng Pharmaceutical Co., Ltd. researches and develops, produces, and sells pharmaceutical products in China. It offers medicines in the form of tablets, capsules, and granules for cardiovascular and cerebrovascular, orthopedic, pediatric, gynecological, traumatology, and anti-infectives. The company was founded in 2002 and is based in Changsha, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 603998.SHG using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024
